aprimeo diagnostics GmbH & Co. KG, a R-Biopharm AG company, starts distribution of the new innovative molecular diagnostics platform Vivalytic from Bosch
Darmstadt, Germany, July 1st 2019 – R-Biopharm AG, a biotechnological company active in the fields of clinical diagnostics and food & feed analysis, began its partnership on March 1st 2018 with Bosch Healthcare Solutions with the goal of developing, manufacturing and commercializing molecular diagnostic assays for the new Vivalytic platform.
Today R-Biopharm AG announced that aprimeo diagnostics GmbH & Co. KG, a R-Biopharm AG company, will execute all activities regarding the commercialization of the Vivalytic platform in several European countries.
“We are very proud and convinced that aprimeo diagnostics will successfully establish the new Vivalytic platform and its assays in the highly competitive Point-of-Care market”, stated Christian Dreher, CEO of R-Biopharm. “Its team of experienced business developers in combination with R-Biopharms product development and manufacturing expertise will enable a successful roll out of this new molecular diagnostic platform providing urgently needed molecular assays for that important market segment.”
“It’s a great honor to be part of a new era in the Point-of-Care market and we are very committed”, said Frank Apostel, Ph.D., Managing Director and Partner of aprimeo diagnostics, former Vice President Business Development & Companion Diagnostic at R-Biopharm AG. “Combining the exceptional benefits of the Vivalytic platform with a broad range of assay applications enables healthcare professionals to make critical decisions improving patients’ care earlier and more accurately than before.”
aprimeo diagnostics GmbH & Co. KG will distribute the Vivalytic platform and its diagnostic assays in Germany, Austria, Switzerland, BeNeLux, France and all Nordic countries starting in the third quarter of 2019.
R-Biopharm AG (Darmstadt, Germany) is a globally active biotechnology company and a leading provider of reliable test systems for clinical diagnostics, companion diagnostics and for analyzing human food and animal feedstuffs. Since 1988, R-Biopharm has been developing innovative products characterized by top quality, reliability and efficiency. A strong sense of responsibility, long-standing experience and a network of more than twenty affiliated companies and subsidiaries in Europe, the US, Brazil,Latin America, China, India and Australia, as well as more than 120 distribution partners, make R-Biopharm a prime partner for clients from retail, industry and public institutions looking for answers and solutions for current and future analytical challenges.
About aprimeo diagnostics
aprimeo diagnostics GmbH & Co. KG is a R-Biopharm AG company, focused on the distribution of innovative, next-level diagnostic solutions. R-Biopharm´s partnership with Bosch Healthcare Solutions enables aprimeo diagnostics to provide the innovative molecular diagnostic platform Vivalytic to healthcare professionals, making it possible for them to take better decisions on therapy for their patients each and every day.
Vivalytic is a universal platform for molecular diagnostics developed by Bosch Healthcare Solutions GmbH which is a wholly owned subsidiary of Robert Bosch GmbH. It enables various laboratory tests to be performed swiftly and in a fully automated manner. The platform unites a wide spectrum of tests on one device and is open for tests from various providers. This enables the portfolio of available tests to grow continuously. Vivalytic is an all-in-one solution that supports the most widespread laboratory test procedures of molecular diagnostics, uniquely integrating all these procedures in a single system.